AI Governance & Assurance · Regulated Drug Development

Validation assurance for probabilistic systems in regulated science.

Where reproducibility is bounded, the validated state is a moving target, and conventional CSV practices were not designed for the sources of risk these systems introduce.

Britt Biocomputing develops and publishes structured frameworks for governing AI in GxP-regulated environments. The frameworks below operate together and extend the FDA seven-step credibility framework, ICH Q9(R1), and the GAMP® 5 / GAMP® AI Guide lineage into territory those standards do not explicitly address.

An integrated body of work

Flagship framework

House of AI Trust™

Five-layer governance architecture

The umbrella framework: organizes AI controls in regulated drug development across five layers — from foundational context-of-use definition through model credibility, composite system controls, monitoring, and human accountability. The other three frameworks below operate within or alongside the House.

Read the flagship guide →
HOUSE OF AI TRUST L5 Business ROI investable L4 Domain + Process Context useful L3 Control Layer VALIDATION · MONITORING · HITL defensible L2 AI Governance manageable L1 Trust Infrastructure possible
L3 is where Britt Biocomputing operates. Four threads run through every layer: Security · Explainability · Communication · Supplier Qualification
Supporting frameworks
02

Probabilistic Validation Lifecycle

Seven-step execution model

Adapts the V-model to systems where reproducibility is bounded rather than absolute. Maps cleanly onto GAMP 5 lifecycle stages while extending them for probabilistic behavior, drift, and continuous verification.

Read →
03

VALID Trust

Four-pillar supplier qualification

A framework for qualifying AI suppliers and inheriting validation evidence in regulated environments. Extends GAMP 5 supplier qualification into non-deterministic upstream components.

Read →
04

Two-Dimensional Error Taxonomy

6 × 6 classification matrix

A public framework for classifying probabilistic AI failures in GxP regulated drug development by both error type and origin, mapped against GAMP 5, ICH Q9(R1), and the FDA seven-step credibility framework.

Read →

Latest writing

July 2026
Self-driving cars don't fail the way human drivers do, and neither does an LLM triaging deviations. Argues the agent harness and the validation harness should be one capture layer with two views — a rule that fires without a trace is an opinion, not evidence.
June 2026
Our public comment on FDA's AI-Enabled Clinical Trial Pilot RFI, arguing that early-phase dosing decisions are the hardest validation problem in drug development — and proposing calibration, perturbation testing, and conformal prediction as metric axes.

Working with Britt Biocomputing

Fixed-fee exposure screens and prioritized risk assessments, scoped engagements that produce inspection-ready evidence, and a fractional AI quality lead for teams that need the role before they can hire for it. Work is sized to the consequence of error and to the maturity of the client's current posture.

Book a free 20-min fit check

Or see the full services overview →